When the holidays roll about, you can count on paying loads of time with relatives and (most likely) eating tons of foods. It is really widespread to knowledge food items guilt about the holidays, especially if you consider treatment to try to eat a well balanced food plan. In reality, a 2020 examine identified 63{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of People seasoned meals guilt through the getaway season.
This getaway time, give on your own grace when it comes to sharing foods with family members and good friends. This is what you have to have to know about food stuff guilt so you can have a pleased vacation period.
What is foodstuff guilt?
Foods guilt is when you experience terrible about anything you’ve got eaten, like you are experience guilty for what you’ve got preferred to consume. Foods guilt can quickly spiral into deeper inner thoughts of shame, primarily for persons with disordered eating.
If you happen to be particularly really hard on you with eating healthy food items, you may close up feeling food items guilt if you eat a thing you look at as harmful.
Why do we come to feel meals guilt?
Food stuff guilt is frequently connected to your romantic relationship with foodstuff. If you continue to keep oneself on a arduous eating plan and “slip,” you might be inclined to come to feel guilty about what you’ve got eaten. This can be a outcome of too significantly tension on on your own to take in in a particular way.
7 strategies for working with meals guilt throughout the holiday seasons
The vacations can be specifically challenging with food stuff guilt. This time of yr brings its very own brand name of pressure — in between family and funds, there’s a ton to offer with. Moreover, you may possibly be sitting down down for meals that are outdoors your nutritional comfort zone, so it can be essential to go into the season outfitted with strategies for managing meals guilt.
bymuratdeniz/Getty Illustrations or photos
1. Check out having a lot less wholesome foodstuff as aspect of a balanced diet
The US Division of Wellbeing and Human Services outlines a “healthy” food plan for individuals to adhere to, breaking down how significantly protein, carbs and many vitamins and minerals you require to eat in a working day. It really is important to harmony “balanced” foodstuff and “harmful” food items, because in moderation, there is certainly almost nothing completely wrong with having stereotypically much less nutrient-rich food items. When you absolutely lower out meals — specially pleasurable treats like ice cream or potato chips — you may possibly locate that you crave them even far more. If you enable yourself to take in these treats once in a when in moderate amounts, eating the healthy foodstuff the relaxation of the time would not come to feel fairly so undesirable.
2. Follow mindful taking in
Aware ingesting is the act of having to pay attention to what you eat and appreciating every chunk. With this observe, you might be equipped to expend a lot more time and energy thinking of your food, according to Harvard’s University of General public Wellbeing. This includes chewing carefully and feeding on bit by bit so you can experience every single bite of foods. Investigate all-around ingesting mindfully has demonstrated that it can minimize nervousness similar to eating, as very well as overeating.
3. Focus on how you really feel soon after ingesting certain foods
Occasionally foods guilt is unavoidable, but what you can do when it occurs is detect that it is really happening. This way, you can actually contemplate why you’re sensation that way. From time to time persons will not even recognize that the responsible sensation is tied to a specified foodstuff or food and why it’s occurring. If you’ve begun a food journal (which we are going to get to soon), you can also compose down these inner thoughts so you can see if there are patterns tied to what thoughts are transpiring and when.
4. Start off a foodstuff journal
Keeping a meals journal can have a constructive result on how you consume. According to Harvard Clinical School, a food stuff journal can assist keep monitor of what you’re feeding on, how considerably you’re ingesting and how you come to feel immediately after. If you might be hunting to strengthen your partnership with food stuff, you can also include why you’re consuming. Nevertheless, it is critical not to develop into way too caught up in checking each and every one thing you happen to be feeding on, as this can flip into obsessive conduct and even disordered taking in. Some investigation has also revealed that when people mature tired of maintaining a meals journal, they give it up and go again to prior meals patterns.
Daniele Mezzadri/Getty Photographs
5. Stay clear of acquiring way too caught up in nutritional mandates
In the exact same way that trying to keep a demanding food journal can switch detrimental, focusing also much on what makes a “healthy” diet regime, on fad eating plans and on everything similar to these stringent ingesting strategies can also have a damaging outcome on you. Diet plans this kind of as keto or Atkins, aren’t always weight loss plans that can be taken care of in the long run — unless proposed if not by your medical doctor. And while counting energy or macros can support you eliminate bodyweight, if that is what you might be aiming for, carrying out this for a prolonged period of time can induce disordered consuming, in accordance to Duke Overall health. Spending far too a great deal notice to these figures can absolutely make you sense guilty if you “go about” what you consider to be the ideal, which can push you even further into sensation responsible about what you might be ingesting.
6. Honor your hunger
Your physique sends indicators to your brain when it feels hungry, and you feel those people pangs when your overall body needs foodstuff. It truly is critical to hear to your body. When it tells you it truly is hungry, you really should feed it. When it tells you it is really full, you need to quit having. Listening to what your physique is telling you is crucial for knowing when and how a great deal to take in.
7. Accept that you ought to have to eat without having punishing on your own after
Give on your own grace when you feel like you’ve got “slipped” due to the fact when it will come to a well balanced food plan, you have not basically slipped at all. You ought to have to have treats when you want them and when it helps make you joyful — and that won’t necessarily mean you require to go to the gym for 2 several hours or skip a food later. Every single day is a new working day, and as prolonged as you might be taking in a nutritious diet plan most of the time, owning a several treats and entertaining foods is completely fantastic. If you are not joyful with what you ate today, remind your self that you can eat one thing else tomorrow — you can find no want to sense guilty.
The information and facts contained in this report is for educational and informational purposes only and is not supposed as wellness or professional medical suggestions. Normally talk to a doctor or other skilled wellness provider about any questions you could have about a professional medical problem or health and fitness targets.
Here’s your weekly update with everything you need to know on the COVID situation in B.C. and around the world.iStock/Getty Images Plus
Article content
Here’s your update with everything you need to know about the COVID situation in B.C. and around the world for the week of Dec. 22-28. This page will be updated with the latest COVID news and related research developments daily throughout the week, so be sure to check back often.
Advertisement 2
This advertisement has not loaded yet, but your article continues below.
Article content
You can also get the latest COVID-19 news delivered to your inbox weeknights at 7 p.m. by subscribing to our newsletter here.
Start your day with a roundup of B.C.-focused news and opinion delivered straight to your inbox at 7 a.m., Monday to Friday.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
Thanks for signing up!
A welcome email is on its way. If you don’t see it, please check your junk folder.
The next issue of Sunrise presented by Vancouver Sun will soon be in your inbox.
We encountered an issue signing you up. Please try again
Article content
Here are the latest weekly B.C. figures given on Dec. 22:
• Hospitalized cases: 349 (down 25) • Intensive care: 35 (up four) • New cases: 609 over seven days ending Dec. 17 (down 50) • Total number of confirmed cases: 391,897 • Total deaths over seven days ending Dec. 17: 22 (total 4,806)
A weekly COVID update from the B.C. Centre for Disease Control revealed 22 deaths of people who died within 30 days of a positive COVID test as of Dec. 17, a drop of five from the previous week.
That number is preliminary, however, and will be updated in later reports as more data comes in.
Advertisement 3
This advertisement has not loaded yet, but your article continues below.
Article content
There were 349 people in hospital who tested positive for the virus, with 35 of those in intensive care, as of Thursday.
Three out of 10 Canadians say they wear masks in public: Study
Three out of 10 Canadians say they mask-up in public, according to a new Angus Reid Institute study.
It says a large group of unmasked Canadians say they wouldn’t like the government to force them to take a more cautionary approach.
Half of Canadians are in favour of re-implementing mask mandates if cases of COVID-19 go up this winter.
Thirty-one per cent of people in the study say they wear a mask more than half of the time in public.
Read the full story here.
Health Canada monitoring massive outbreak ‘starting to rip through’ China
Health Canada says it’s monitoring the growing wave of COVID-19 cases in China, which experts are warning could kill a million people in the next few months, as the country allows the virus free rein.
Advertisement 4
This advertisement has not loaded yet, but your article continues below.
Article content
China has done a dramatic U-turn in recent weeks, ending its zero-COVID policy that required regular COVID tests, mandatory quarantine and sweeping, restrictive lockdowns to control the virus.
Dr. Isaac Bogoch, an infectious disease physician at Toronto’s University Health Network, said ending the zero-COVID policy, especially in a population with lower vaccine rates, will mean a wave of new infections.
“They don’t have the same degree of community-level protection that other parts of the world have, either through vaccination, through recovery from infection or from both,” he said. “What we’re seeing obviously, very sadly, is that, you know, the virus is starting to rip through populations.”
Read the full story here.
Advertisement 5
This advertisement has not loaded yet, but your article continues below.
Article content
— The Canadian Press
China hospital data absent from WHO’s latest COVID reports, raising concern
The World Health Organization has received no data from China on new COVID-19 hospitalisations since Beijing lifted its zero-COVID policy, prompting some health experts to question whether it might be hiding information on the extent of its outbreak.
However, the WHO has said gaps in data might be due to Chinese authorities simply struggling to tally cases.
WHO weekly reports showed rising hospitalisations for COVID-19 in China running up to Beijing’s Dec. 7 decision to ease restrictions on movement that were meant to stamp out any transmission of the virus but which prompted extraordinary public protests and hobbled the world’s second largest economy.
Advertisement 6
This advertisement has not loaded yet, but your article continues below.
Article content
They peaked at 28,859 through to Dec. 4, according to a WHO graph, the highest reported figure in China since the virus first emerged three years ago, but figures have been absent in the last two reports.
Regular exercise protects against fatal COVID, study shows
Men and women who worked out at least 30 minutes most days were about four times more likely to survive COVID-19 than inactive people, according to an eye-opening study of exercise and coronavirus outcomes among almost 200,000 adults in Southern California.
The study found that exercise, in almost any amount, reduced people’s risks for a severe coronavirus infection. Even people who worked out for as little as 11 minutes a week — yes, a week — experienced lower risks of hospitalization or death from covid than those who moved about less.
Advertisement 7
This advertisement has not loaded yet, but your article continues below.
Article content
“It turns out exercise is even more powerful than we thought” at protecting people from severe covid, said Robert Sallis, a clinical professor at Kaiser Permanente Bernard J. Tyson School of Medicine in Los Angeles and senior author of the new study.
The findings add to mounting evidence that any amount of exercise helps lower the ferocity of coronavirus infections, a message with particular relevance now, as holiday travel and gatherings ramp up and COVID cases continue to rise.
Read the full story here.
— The Washington Post
Immunity debt is not a myth: Why it seems like everybody is sick right now
Although Canada has never maintained a running tally of seasonal illnesses, it’s clear that the country is being absolutely hammered by a tidal wave of flu and respiratory viruses right now.
Advertisement 8
This advertisement has not loaded yet, but your article continues below.
Article content
Children’s hospitals have been overwhelmed since Halloween with what one Montreal physician has described as an “explosive” flu season. The country’s critical shortage of childhood cold medication also continues apace, with Health Canada now saying the backlog won’t fully clear until sometime in 2023.
There is compelling evidence that much of this sickness is a side effect of COVID restrictions — although there remain members of the medical community who are resolutely claiming otherwise.
The basic idea is that social distancing, masking and school closures not only slowed the circulation of COVID-19, but also curbed the usual spread of illnesses such as the flu, respiratory syncytial virus (RSV) and common cold. And now, with civil society reopened, all these seasonal viruses are playing a vicious game of catchup.
Advertisement 9
This advertisement has not loaded yet, but your article continues below.
Article content
Read the full story here.
— Tristin Hopper
China’s COVID wave spurs fears that dangerous new variant could emerge
The tsunami of COVID-19 that’s taking hold across China is spurring concern that a dangerous new variant could emerge for the first time in more than a year, just as genetic sequencing to catch such a threat is dwindling.
The situation in China is unique because of the path it’s followed throughout the pandemic. While almost every other part of the world has battled infections and embraced vaccinations with potent mRNA shots to varying degrees, China largely sidestepped both. The result is a population with low levels of immunity facing a wave of disease caused by the most contagious strain of the virus yet to circulate.
Advertisement 10
This advertisement has not loaded yet, but your article continues below.
Article content
The expected surge of infections and deaths are taking hold in China within a black box since the government is no longer releasing detailed COVID data. The rise has medical experts and political leaders in the U.S. and elsewhere worried about another round of disease caused by the mutating virus. Meanwhile, the number of cases sequenced globally each month to find those changes has plunged.
“There will certainly be more Omicron subvariants developing in China in the coming days, weeks and months, but what the world must anticipate in order to recognize it early and take rapid action is a completely new variant of concern,” said Daniel Lucey, a fellow at the Infectious Diseases Society of America and professor at Dartmouth University’s Geisel School of Medicine. “It could be more contagious, more deadly, or evade drugs, vaccines and detection from existing diagnostics.”
Advertisement 11
This advertisement has not loaded yet, but your article continues below.
Article content
Read the full story here.
— Bloomberg News
What are B.C.’s current public health measures?
MASKS: Masks are not required in public indoor settings though individual businesses and event organizers can choose to require them.
Masks are also encouraged but not required on board public transit and B.C. Ferries, though they are still required in federally regulated travel spaces such as trains, airports and airplanes, and in health care settings.
GATHERINGS AND EVENTS: There are currently no restrictions on gatherings and events such as personal gatherings, weddings, funerals, worship services, exercise and fitness activities, and swimming pools.
There are also no restrictions or capacity limits on restaurants, pubs, bars and nightclubs; and no restrictions on sport activities.
Advertisement 12
This advertisement has not loaded yet, but your article continues below.
Article content
CARE HOMES: There are no capacity restrictions on visitors to long-term care and seniors’ assisted living facilities, however, visitors must show proof of vaccination before visiting. Exemptions are available for children under the age of 12, those with a medical exemption, and visitors attending for compassionate visits related to end-of-life.
Visitors to seniors’ homes are also required to take a rapid antigen test before visiting the facility or be tested on arrival. Exemptions to testing are available for those attending for compassionate visits or end-of-life care.
How do I get vaccinated in B.C.?
Everyone who is living in B.C. and eligible for a vaccine can receive one by following these steps:
• Get registered online at gov.bc.ca/getvaccinated to book an appointment in your community. • Or, if you prefer, you can get registered and then visit a drop-in clinic in your health authority. • The system will alert you when it is time to go for your second dose. • The same system will also alert you when it is time for your booster dose.
Advertisement 13
This advertisement has not loaded yet, but your article continues below.
Article content
We apologize, but this video has failed to load.
Where can I get a COVID-19 test?
TESTING CENTRES: B.C.’s COVID-19 test collection centres are currently only testing those with symptoms who are hospitalized, pregnant, considered high risk or live/work with those who are high risk. You can find a testing centre using the B.C. Centre for Disease Control’s testing centre map.
If you have mild symptoms, you do not need a test and should stay home until your fever is gone. Those without symptoms do not need a test.
TAKE-HOME RAPID ANTIGEN TESTS: Eligible British Columbians over the age of 18 with a personal health number can visit a pharmacy to receive a free take-home test kit containing five COVID-19 rapid antigen tests.
We apologize, but this video has failed to load.
More news, fewer ads: Our in-depth journalism is possible thanks to the support of our subscribers. For just $3.50 per week, you can get unlimited, ad-lite access to The Vancouver Sun, The Province, National Post and 13 other Canadian news sites. Support us by subscribing today: The Vancouver Sun | The Province.
B.C. government continues the pandemic wage top-up for care home workers
The viral immunity debate has no simple answer — but masks make a difference, says researcher
UBC researchers discover compound that could halt colds, COVID
Holiday parties are back as British Columbians tap a need to be together
Share this article in your social network
Advertisement 1
This advertisement has not loaded yet, but your article continues below.
Gisela Donahue is originally from Cape Town, South Africa. She’s a physical fitness coach and owner of Inspire Physical fitness. S LURAY Pictures/Contributed
Staying nutritious in the course of the getaway year can be a obstacle for any age. The Keys Weekly a short while ago sat down with Gisela Donahue, conditioning mentor and proprietor of Inspire Conditioning, to discover extra about her journey and some guidelines on how to remain balanced and get ready for 2023.
We lived in Naples because 2017 prior to transferring in this article in 2021. Ahead of, we lived in Southern Vermont on the other hand, I am at first from Cape Town, South Africa. My partner, Paul, is from Boston. He was part of a ski cafe team, and soon after our 1st baby, Kylie, we made a decision to relocate south for the hotter weather.
When I was in Naples, I worked with a large amount of state clubs, and I finished up loving it. My client’s objectives went from the regular “I want to lose 10 kilos.” to “I want to functionality, get up the stairs, and enjoy everyday living.” It grew an additional total side of my mind. In the Keys, I have a great blend of the two varieties of aims.
Considering that it’s turn out to be extra of a love for wellness and physical fitness than “I shed 10 lbs,” I obtain I hook up with a lot far more individuals as they can see the price of the function they are putting in. I often hear the feed-back: “We went on holiday vacation, and I could lift my very own suitcases. I went to the seashore with my grandkids, and I could retain up.”
If it is about each day residing, then you want to do it, and you do it with a various angle. It’s a whole other way of considering. Health is a way of living it’s a journey. And it is not just for the limited time period it’s a lifetime.
My organization is primarily 1-on-one particular, and I have labored with consumers ages 16 to 93. I have also performed groups in advance of. The team setup can inspire customers. I initially experienced a studio at Cirque Salon till September, but now I have produced a studio at my home. I also have digital customers and some purchasers I drive to see. The digital also will work if people today are traveling or snowbirds and want to stay in good shape.
The main private schooling focuses on energy and stability. Also, concentrating on obtaining a potent main to depend on. It doesn’t will need to be hefty weights. The “old mentality” is females did not realize the gain of weights and principally did cardio workout.
Therefore, we operate with a wide variety of training machines this sort of as lesser dumbbells, resistance bands, spinning bike, Pilates workouts and machines, drinking water rower device and shorter burst of heart amount, AKA “hit” exercise routines. I regulate to what my consumer requirements as I like to get to know them and what functions for them.
Getting your main and glutes strong is vital. Nevertheless, if there is an training anyone hates, like burpees, I will advise one more training that however targets the spot. However, some clientele come to appreciate it.
For me, work out helps distinct my head I enjoy it. But you continue to have to come across the element in your brain where by you assume it is essential to your existence. I genuinely really do not really feel like I perform — I am obnoxiously in adore with what I do.
Element of my education is on nutrition. I really do not thrust nourishment, but I am there for them if they want for my support. I have discovered retaining it basic has worked for me. Portion dimension and understanding what food stuff classes meals slide in. I realized what is good for my overall body and around what I really should consider in.
Gisela Donahue functions with a wide range of customers. S LURAY Images/ContributedGisela Donahue owns Inspire Fitness. S LURAY Images/Contributed
How did I get commenced? All my everyday living, I was athletic. Then, in my mid-20s, I walked a extensive route of infertility. I obtained a ton of body weight for the duration of that time. As soon as Kylie was born, we went to the mall together. I went to wander the stairs at the shopping mall and experienced to halt two times to catch my breath. I was only 30. So, I experienced gotten so shed in my journey towards starting to be a mother that I hadn’t taken care of myself. It was a turning issue.
The place we lived in southern Vermont, it was a smaller town, so there weren’t any huge gyms or trainers for that reason, I started off understanding and figuring it out for myself inside the year, I went from a sizing 14 to a size 2. I am 5-foot 3-inches tall, so it was sizeable. I then entered my initially fifty percent marathon people today observed me running and schooling and started out inquiring me for advice. Why really do not I do this for a residing? I did all the certifications I could and took all the classes. So, one by 1, I commenced helping persons.
I took responsibility initial and recognized what it is like to be on the other side.
There are some easy points to assume about to assist you get started out — do you like to function in a group? Glimpse for Pilates or Zumba or make a strolling team and meet up with up. Do you want to be outside? Is it walking or jogging? What variety of man or woman are you, and what will make it straightforward? What do you like the most?
But you must demonstrate up. Brief-phrase plans can function, but when you stop, it goes, compared to seeing it as a life span determination. Our bodies are intended to go, heart, bone and joint health. Obtain what will work for you but then doing the job with me will help you commit.
Why do we hold out for Jan. 1? Folks like to procrastinate, so they like to have a long term day. But I say start off now. You never know what lies in advance, so why not commence right now? The ideal to indulge more than the major. Portion measurement, understand to halt, and do not carry it earlier the holiday seasons. Do not think that helps make you truly feel gross right after. If your abdomen feels bloated and sore afterward, why take in it?
When I imagine of my holiday meal, I choose my part, my veg, but I never go up for seconds or thirds. Have your dessert and your glass of wine. Select what you really like, portion sizing, and be completed.
Top rated tips to enable you:
Follow self-control and obligation, but don’t deprive yourself.
Continue to be lively — go on a relatives stroll.
I operate with clients to get them to adore staying lively, so it lasts. There are going to be occasions when it is tough and challenging to work by way of an physical exercise, but then they say, “I just did that!”
Just give me 50 minutes, some drinking water bottles, and a chair, and I can get you sweating.
Inspire Fitness’s hrs are Monday thru Friday. Adhere to on IG @inspirefitnessfl and make contact with for a session and pricing 802-558-7982.
Curious about heading down the plant-dependent route for bodyweight reduction? Try out commencing with these ideas.
1. Make a decision on Your Definition of Plant-Based
There’s no single definition of plant-based mostly having, so it’s up to you to come to a decision which style of this food plan works for you. For example, your nutritional sample could search like veganism, which nixes all foods derived from animals lacto-ovo-vegetarianism, which permits eggs and dairy or pescatarianism, which involves seafood. There is even a flexitarian diet plan, which suggests you will however consume animal goods listed here and there, but mostly adhere to a plant-primarily based consuming sample. Investigate has associated veganism, lacto-ovo-vegetarianism, pescetarianism, and flexitarianism with bodyweight loss. Finally, you have options and identifying your very own definition will offer way for your nutritional choices.
Prior to diving in, you could also want to give some assumed to how this nutritional pattern will influence your lifestyle. For instance, heading vegan may existing extra problems in social configurations or although eating out, and will call for much more substitutions in cooking and baking at property. Broader versions of vegetarianism, on the other hand, may possibly be much easier to abide by.
2. Stay clear of an All-or-Absolutely nothing Mentality
Try to remember, your eating plan is up to you — so even if you select a plant-centered having sample, it doesn’t suggest you can by no means depart from it. You may possibly also discover you like to simplicity into plant-forward having slowly, alternatively than in one fell swoop. “Maybe you are not ready to go entirely plant dependent appropriate now that is fine,” claims Newlin. “Perhaps start out by including additional veggies to foods you currently enjoy and consuming fruit as dessert.”
Substituting fruit for bigger-calorie desserts could amplify your body weight loss attempts. A examine printed in 2019 in Frontiers in Diet revealed that having fresh new, whole fruits was not likely to lead extra energy and physique excess fat, and could even help avoid chubby.
3. Find out About Plant-Based mostly Swaps
Switching to a plant-based mostly eating plan will not call for tweaking your macros or counting your calories, but it does demand a little bit of training. To be organized for this way of feeding on, just take some time to learn about a variety of plant-based substitutions you can make. “Experiment with various types of plant-primarily based proteins and recipes,” implies Mitri — or master about how to use flax “eggs” and plant oils in put of animal solutions in baking.
Frequently, these plant-based substitutions consist of fewer energy and extra fat than their animal counterparts, therefore maybe supporting pounds loss. A 3-ounce serving of tofu, for example, supplies just 63 energy, whereas a 3-ounce hen breast has 122 energy, for every the U.S. Division of Agriculture (USDA). Equally, 1 cup of almond milk incorporates 37 energy and 3 grams of fat, as opposed with the 122 calories and 4.6 grams of body fat in 1 cup of 2 p.c cow’s milk, per the USDA.
4. Do not Forget About Protein
Lacking out on protein is a popular pitfall of a plant-dependent eating plan, primarily if you have very long depended on animal goods for this macronutrient. As you changeover away from meat, don’t neglect to consist of protein-prosperous plant foods like beans, legumes, tofu, seitan, and tempeh.
Protein could be one critical to productive weight loss. Though research doesn’t show that plant protein has any significant edge in excess of animal protein for dropping lbs, reports counsel getting enough of this macronutrient in truth supports losing bodyweight.
5. Hold Meal Planning Uncomplicated
“Don’t complicate plant-based ingesting!” advises Newlin. “You can toss jointly a healthy plant-based mostly meal in considerably less than 10 minutes.” Her go-to meal: a bag of frozen precooked rice, a bag of stir-fry greens, some shelled edamame, and a smaller amount of money of bottled sauce. “In the starting, continue to keep it easy and undertaking into attempting new recipes as you really feel additional assured.”
Easy, dwelling-cooked meals are not only a boon to chaotic weeknights they may well also lead to a lower variety on the scale In a study in Annals of Behavioral Medication, people today who planned their meals had reduce human body mass index (BMI) than those people who did not.
6. Get Strategic for Satiety
Downing a bowl of salad greens for lunch is an great way to consider in micronutrients and anti-oxidants, but it might leave you hungry by 2 p.m. On a plant-centered food plan, it is beneficial to prepare for meals that retain you complete. “Prioritize such as a protein and fiber source with each individual meal, and limit the number of refined carbs in your diet regime,” Mitri indicates. By being contented through the day, you’ll reduce the chance of overeating when mealtime or snacktime rolls all over.
7. Shell out Interest to Food stuff Labels
Just mainly because a food items advertises alone as plant-dependent does not make it healthy. Get savvy with foods labels so you can distinguish when a packaged meals is essentially a excellent choice. “Read the labels, pay focus to saturated fat, extra sugar, and the sodium content in packaged meals,” Newlin recommends. “Junk foodstuff is however junk food stuff even when wrapped in plant-primarily based labeling.” This is an especially smart transfer for reaching a wholesome body weight, since extremely processed meals are associated with fat achieve, for each the National Institutes of Wellness.
The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.
Methods
PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years vs ≥50 years) and vaccination status (yes vs no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031.
Findings
Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir.
Interpretation
Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.
Funding
UK National Institute for Health and Care Research
Introduction
Early treatment of COVID-19 with direct-acting antiviral drugs in the community could plausibly prevent deterioration, speed up recovery, and reduce health-care use in the community, viral shedding, and, the need for hospital admission. Molnupiravir is an oral antiviral that was initially developed for influenza,
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Molnupiravir is a prodrug: the ribonucleoside analogue β-d-N4-hydroxycytidine is metabolised to its triphosphate form in cells, and then competes with the naturally occurring nucleotides cytidine triphosphate and uridine triphosphate.
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Research in contextEvidence before this studyWe searched PubMed with the terms (randomised OR trial) AND (molnupiravir) AND (COVID* OR SARS-CoV-2 OR SARS-CoV) AND (systematic review) for articles published in any language up to Sept 5, 2022. Our search identified ten results. The two most comprehensive reviews were living reviews synthesising the findings of six trials of molnupiravir compared with either standard of care or placebo. These reviews suggested that molnupiravir reduces the frequency of hospital admissions in patients with mild-to-moderate COVID-19. WHO’s living guideline recommends use of molnupiravir in outpatients with mild-to-moderate COVID-19 who are at the highest risk of hospital admission. The largest randomised clinical trial identified by the evidence syntheses was the placebo-controlled, phase 3 MOVe-OUT trial. In this trial of 1433 unvaccinated outpatients with COVID-19, molnupiravir was associated with a relative reduction of roughly 30{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in the primary outcome—hospitalisations and deaths—up to 29 days after randomisation. Notably, the reduction in hospitalisations and deaths had been closer to 50{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in the trial’s interim analysis (after 762 participants had been recruited). The reason for this difference is unclear. Several trials of molnupiravir have been done in India, but full peer-reviewed findings have not yet been published. In the AGILE CST-2 trial, which included 180 participants (both vaccinated and unvaccinated), time to a negative PCR test was shorter in the molnupiravir group than in the placebo group (8 days vs 11 days), but this difference was not significant.Added value of this studyMolnupiravir did not reduce hospitalisations or deaths in a community-based vaccinated adult population with COVID-19 who were at increased risk of an adverse outcome, either overall or in any patient subgroups. However, molnupiravir was associated with reduced time to recovery overall and for key individual symptoms, reduced health-care seeking for some primary care services, and reduced viral load. Trials of molnupiravir have previously been done in largely unvaccinated participants before the emergence of the omicron variant. Our trial provides an estimate of the effectiveness of molnupiravir in a multiply vaccinated population when the omicron SARS-CoV-2 strain was dominant.Implications of all the available evidenceThe use of molnupiravir to treat confirmed SARS-CoV-2 infection in vaccinated adults who are at increased risk of an adverse outcomes when omicron was the dominant circulating variant did not reduce hospital admissions or deaths, both of which are already very infrequent, but did reduce time to recovery (and viral detection and load in a substudy).
The largest trial of molnupiravir so far is MOVe-OUT,
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
a placebo-controlled, industry-funded phase 3 trial in unvaccinated, non-hospitalised patients with COVID-19 at high risk of adverse outcomes. The final results suggest a 30{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} reduction in hospital admissions and deaths with molnupiravir treatment compared with placebo.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
which included 180 vaccinated and unvaccinated participants, suggested that molnupiravir was associated with a shorter time to a negative PCR test compared with placebo (8 days vs 11 days), although this difference was not significant.
The effectiveness of molnupiravir in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19 has not yet been established. We aimed to assess the effectiveness of molnupiravir in reducing hospital admissions or death, or both, in this population.
Methods
Study design and participants
PANORAMIC is a national, multicentre, primary care, open-label, multigroup, prospective, platform adaptive trial of early treatments for COVID-19 in the UK. The trial opened for recruitment on Dec 8, 2021, and is ongoing. Full details of the protocol are in the appendix (p3). Platform trials allow for multiple treatments for the same disease to be tested simultaneously. A master protocol defines prospective decision criteria for stopping randomisation to interventions for futility, declaring interventions superior, or adding new interventions.
Master protocols to study multiple therapies, multiple diseases, or both.
Interventions assessed in PANORAMIC include molnupiravir (from December, 2021, to April, 2022) and nirmatrelvir–ritonavir (which remains open to recruitment as of December, 2022). However, there were no trial adaptations, and there was only a short period of overlap with nirmatrelvir–ritonavir recruitment while participants were being recruited to the interventions discussed in the Article.
Eligible people were in the community (ie, not in hospital), aged 50 years or older (or 18 years or older with relevant comorbidities; appendix p 14), had COVID-19 symptoms that had started within the previous 5 days, and had had a positive PCR or rapid antigen SARS-CoV-2 test within the past 7 days. People were excluded from participating if they were pregnant or breastfeeding, of childbearing potential and unwilling to use effective contraception, already taking molnupiravir, or allergic to molnupiravir. The complete inclusion and exclusion criteria are in the appendix (p 14).
The UK Medicines and Healthcare products Regulatory Agency and the South Central-Berkshire Research Ethics Committee of the Health Research Authority approved the trial protocol. Online informed consent was obtained from all participants. We vouch for the accuracy and completeness of the data and for fidelity to the protocol. An independent trial steering committee and data and safety monitoring committee provided trial oversight.
Randomisation and masking
Potentially eligible people were screened, recruited, and enrolled via 65 PANORAMIC General Practice Hubs encompassing 4509 general practices across the UK. Participants were also recruited online and by telephone by the central trial team. Eligible participants were randomly assigned (1:1) by medical or research professionals to receive molnupiravir plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years vs ≥50 years) and vaccination status (yes vs no). Participants and members of the trial team responsible for recruitment, follow-up, and monitoring of participants were aware of group assignment. Trial investigators and recruiting clinicians were masked to emerging results; only unmasked statisticians and the independent members of the data and safety monitoring committee were granted access to unmasked results until the decision was made to close recruitment to molnupiravir.
Procedures
Participants in the molnupiravir group were asked to take 800 mg molnupiravir orally twice daily for 5 days. These participants were urgently couriered a participant pack containing molnupiravir (along with dosing and safety information) and a pregnancy test (only for use by participants of childbearing potential). Participants in both groups were emailed or posted a trial information booklet. Usual care in the UK National Health Service (NHS) for COVID-19 in the community is largely focused on managing symptoms with antipyretics.
National Institute for Health and Care Excellence COVID-19 rapid guideline: managing COVID-19.
However, patients at very high risk (ie, those with impaired immune systems or who are extremely clinically vulnerable—roughly 1·8 million people in the UK) are eligible to receive monoclonal antibodies (sotrovimab), intravenous antivirals (remdesivir), and oral antivirals (molnupiravir or nirmatrelvir–ritonavir) from specialist regional COVID-19 clinics.
NHS England Interim clinical commissioning policy: neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19.
Prescription of monoclonal antibodies and antiviral agents other than molnupiravir in the course of usual care was permitted, and monoclonal antibody use was recorded in an online diary. Participants assigned to the molnupiravir plus usual care group would not have received additional molnupiravir, but those assigned to the usual care group could have received molnupiravir through the NHS.
Participants were followed up through an online daily diary for 28 days after randomisation. Non-responders were telephoned on days 7, 14, and 28. Participants were asked to rate symptoms (eg, fever, cough, breathlessness) on an ordinal scale as “no problem”, “mild problem”, “moderate problem”, or “major problem”, to rate how they were feeling on a scale from zero to ten (in which zero corresponded with the worst one can imagine, and ten with the best one can imagine), and to report whether they had been hospitalised or required contact with health and social services, whether they felt fully recovered, whether they were taking over-the-counter medication for their COVID-19 symptoms, whether the number of people in the household with COVID-19 had changed, and whether they had taken molnupiravir (if applicable). At day 14 and 28, participants were also asked to complete the EQ-5D-5L to assess health-related quality of life. Participants could nominate a trial partner to help to provide follow-up data. We obtained consent from participants to access health-care use data from their general practices and health-care records. Additional questions about long-term symptoms and health-care use were asked 3 months and 6 months after randomisation, but these results are not reported here.
Virology substudy
Participants enrolled at all sites between March 23 and April 27, 2022, were offered the opportunity to participate in an intensively and non-intensively sampled virology cohort. Those who took part were couriered European In-Vitro Diagnostic Devices Directive-approved sampling kits and instructions for nasal and pharyngeal swab and dried blood spot self-sampling. They were asked to post the samples to the virology-processing site (postage and packaging were pre-paid). Participants in the intensive sampling cohort were asked to provide daily nasal or pharyngeal swabs for the first 7 days and on day 14 (or day 13 or 15). In the non-intensive sampling cohort, participants were asked to provide nasal or pharyngeal swabs on days 1, 5 (or day 4 or 6) and 14 (or day 13 or 15). Participants in the molnupiravir plus usual care group were asked to take their first sample before the first dose of molnupiravir, whereas those in the usual care group were asked to provide their first sample the day after randomisation. All participants in the virology substudy were asked to provide three finger-prick dried blood spot samples, one each on days 1, 5 (or day 4 or 6), and 14 (or day 13 or 15).
Outcomes
The primary outcome was all-cause, non-elective hospital admission or death within 28 days of randomisation. Hospital admission was defined as at least one overnight stay in hospital, or at least one night in a hospital-at-home programme (a service in which patients who are not formally admitted to hospital are cared for and monitored by hospital clinicians at home) after hospital assessment. Spending time during the day in a hospital emergency department was classified as an emergency department attendance. Overnight stays in the emergency department were counted as admissions. Hospitalisation for elective procedures planned before trial entry was not counted in our primary outcome.
Secondary outcomes included time to self-reported recovery (which was defined as the first instance that a participant reported feeling fully recovered from COVID-19), time to early sustained recovery (recovery by day 14 sustained until day 28), time to sustained recovery (ie, time to the date the participant first reported recovery that was maintained until 28 days), self-reported wellness, time to initial alleviation of symptoms (ie, time to the first day participants reported no or only minor symptoms), time to sustained alleviation of symptoms (ie, time to first day participants reported no or only minor symptoms that subsequently remained minor or non-existent until 28 days), time to initial reduction of symptom severity, contact with health or social services, hospital assessment without admission, oxygen administration, new household COVID-19 infections, and safety outcomes. The appendix (pp 109–10) contains full details of all secondary outcomes. The primary outcome of the virology substudy was undetectable viral load at day 7. Other outcomes for the virology substudy are detailed in the appendix (p 155–56).
Statistical analysis
The sample size calculation and statistical analysis are detailed in the appendix (pp 98, 164). The sample size was initially calculated on the basis of a 3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} event rate with usual care, with an intervention expected to reduce the frequency of hospitalisation or death rate to 2{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} (ie, a 33{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} relative reduction). Based on this calculation, we needed to recruit at least 5300 participants to each group to ensure a 5{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} level of significance and 90{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} power. However, the aggregate (masked) proportion of participants admitted to hospital was lower than anticipated, so the sample size calculation was revised to 16 578 per group (90{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} power) or 12 534 per group (80{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} power), which involved assuming event frequencies of 1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in the control group and 0·67{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} in the intervention group. This recalculation of sample size was done for the overall proportion of hospitalisations and deaths, and did not affect any decision criteria thresholds or interpretation of the final results.
The primary analysis population was defined as all eligible participants who were randomly assigned. Participants who were randomly assigned but subsequently found to be ineligible for inclusion were excluded from the analysis. Participants were analysed according to the group they were allocated to, irrespective of protocol deviations. To analyse the primary outcome, we used a Bayesian logistic regression model with weakly informative Cauchy priors (appendix p 167) that was regressed on treatment group, comorbidity, and stratification covariates (age and vaccination status). 95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} Bayesian credible intervals (95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCIs) were calculated. The success thresholds at final and interim analysis were prespecified (appendix pp 170–71) and were dependent on the number of interim analyses, which was a function of the speed of enrolment. If no interim analyses were done (eg, in the case of very fast enrolment), the success threshold at the final analysis was 0·975. Only one participant in the analysis population received treatment that differed from their randomised allocation, so the model fit in the sensitivity analysis was nearly identical to the primary analysis model fit. If data for the primary outcome were missing for more than 5{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of the study population, a sensitivity analysis, in which missing data would be imputed by multiple imputation, was planned (appendix pp 141–42).
The sample size for the virology substudy was based on simulations from a viral dynamic model from early 2020,
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies.
which suggested that inclusion of 30 patients per group would detect a 2·5 times increase in viral clearance (which translates into roughly double the rate of undetectable viral loads at day 7) in patients who started treatment within 5 days of symptom onset (with 90{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} power and an α of 0·05) compared with those receiving usual care. Clinical improvement could be associated with smaller decreases in viral load, and viral dynamic modelling leveraging time-series viral-load data can detect much smaller drug effect sizes.
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.
Furthermore, 300 participants would provide a 95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} probability of seeing at least one example of a SARS-CoV-2 mutation occurring in at least 1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of participants. Viral sequencing analysis will be reported in another paper.
For secondary time-to-event outcomes we used a Bayesian piecewise exponential model with weakly informative normal priors and four time segments (based on quartiles for the observed time to response) to estimate the hazard ratio for the treatment versus the control group, adjusting for age, vaccination status, and any comorbidity. We used the χ2 test or Fisher’s exact test to analyse binary outcomes with a low event frequency. These results were reported descriptively by treatment group. Early sustained recovery was analysed with a Bayesian logistic regression model, in which group assignment, age, vaccination status, and comorbidity status were covariates.
Because PANORAMIC is a pragmatic trial of a licensed, approved drug in its licensed population, we adopted a pharmacovigilance strategy. Thus, standard adverse event data were not routinely captured. Our strategy was to comprehensively capture safety data for serious adverse events and adverse events for which data are scarce. There was, however, a robust mechanism in place for participants to seek advice on the management of troublesome adverse events. All analyses were done in STATA (version 16.1) and R (version 4.2.1). This trial is registered with ISRCTN, number 30448031.
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Results
Between Dec 8, 2021, and April 27, 2022, 25 783 participants were enrolled and randomly assigned, 12 821 to molnupiravir plus usual care and 12 962 to usual care alone (figure 1). After randomisation, 47 people in the molnupiravir plus usual care group and 28 in the usual care group were judged ineligible. Data were extracted on Oct 11, 2022. A further 628 participants were randomised to other treatment groups after April 27, 2022, but they were not included in the analyses presented here.
The mean age of participants was 56·6 years (SD 12·6). 17 703 (69{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 25 708 had comorbidities and 24 290 (94{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 25 708 had received at least three doses of a SARS-CoV-2 vaccine. Baseline characteristics were similar between groups (table 1).
Table 1Baseline characteristics
Data are mean (SD), n ({35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}), or median (IQR).
Of the 12 338 participants assigned to molnupiravir plus usual care who provided medication-use information, 11 731 (95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) reported taking molnupiravir for 5 days. Less than 1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of participants in both groups received monoclonal antibody treatment separate from the PANORAMIC trial (table 1).
Because of the rapid accrual of participants relative to the period during which the primary endpoint could be reached (28 days), no interim analyses were done. Thus, there was no adjustment to the success thresholds as prospectively outlined in the analysis plan. Data for the primary outcome were missing for only 654 (3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of the population, and therefore no prespecified imputation of missing data was done.
Data for the primary outcome were available for 25 054 (97{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) participants and included in this analysis. Hospitalisations or deaths were recorded in 105 (1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 525 (1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) in the usual care group (adjusted odds ratio 1·06 [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI 0·81–1·41]; probability of superiority 0·33). Results in an analysis unadjusted for baseline covariables were identical. There was no evidence of a treatment interaction in any patient subgroups (figure 2).
Figure 2Forest plot of subgroup analyses of hospitalisation or death, or both
Median time from randomisation to first recovery was 9 days (IQR 5–23) in the molnupiravir plus usual care group and 15 days (7–not reached) in the usual care group (estimated benefit 4·2 days [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI 3·8–4·6]; posterior probability of superiority of >0·99; figure 3; table 2). Estimated median time to first recovery was 10·4 days (95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI 10·1–10·6) in the molnupiravir plus usual care versus 14·6 days (14·2–15·0) in the usual care group (hazard ratio 1·36 [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI 1·32–1·40]), which met the prespecified superiority threshold (table 2). Subgroup analyses showed that this benefit was consistent across all studied groups (figure 4).
Figure 3Time from randomisation to first reported recovery from COVID-19
Table 2Primary and secondary outcomes
Data are n, n/N ({35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}), median (IQR), or mean (SD). 95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI=95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} Bayesian credible interval.
Figure 4Forest plot of subgroup analysis of time to first reported recovery from COVID-19
Compared with the usual care group, participants in the molnupiravir plus usual group more often reported early sustained recovery, higher self-rated wellness (appendix p 182), reduced time to sustained recovery, reduced time to alleviation of all symptoms (and each symptom; appendix pp 183–84), reduced time to sustained alleviation of all symptoms (appendix pp 183–84), reduced time to reduction of symptom severity (appendix p 185), fewer moderate or severe symptoms at days 7, 14, and 28 (table 2), and less contact with general practitioners (table 2). Emergency department attendance and the number of new infections in participants’ households were similar in both groups (table 2).
In the intensively sampled virology cohort, SARS-CoV-2 viral load was undetectable on day 7 in seven (21{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 34 participants in the molnupiravir plus usual care group and one (3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 39 in the usual care group (p=0·039; table 3). The geometric mean viral load was 6603 (SD 25) in the molnupiravir plus usual care group and 8 5025 (24) in the usual care group (p<0·0001; table 3). In the less intensively sampled virology cohort, viral loads were lower in the molnupiravir plus usual care group than in the usual care group at day 5 (table 3). Viral load at day 14 was low overall but slightly higher in the molnupiravir plus usual care group than in the usual care group (table 3). Serious adverse events were reported for 50 (0·4{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 934 in the usual care group (appendix p 188). No serious adverse events that were definitely related to the intervention were reported. 145 (1·1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) of 12 774 participants in the molnupiravir plus usual care group withdrew because of adverse effects that were attributed to molnupiravir. No adverse events of special interest were reported.
Table 3Outcomes from the viral substudy
Data are n/N ({35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}) or geometric mean (geometric SD).
Discussion
This analysis of the largest randomised trial involving people vaccinated against SARS-CoV-2 infection who are at increased risk of adverse outcomes in the community and unwell with COVID-19 showed that the early addition of molnupiravir to usual care did not reduce hospital admissions or death (which were low in both treatment groups). However, participants in the molnupiravir plus usual care group recovered faster than those in the usual care group, had a higher rate of early sustained recovery, and had fewer general practitioner consultations. This faster patient-reported recovery was consistent with a reduction in detectable virus and viral load in participants who received molnupiravir compared with those who received usual care only. We did not identify any patient subgroup in which molnupiravir was associated with a reduced chance of hospital admission, and benefits in terms of time to first self-report of recovery were evenly distributed across subgroups. We recorded few serious adverse events in the trial, and none definitely related to molnupiravir.
Two living reviews of treatments for COVID-19—a WHO living guideline
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Data from the other three trials were made accessible to WHO but have not been shared publicly. Concern has been raised about the lack of public sharing or formal publication of the findings of these three trials, along with those of nine others, all of which were done in India.
Drug treatments for COVID-19: living systematic review and network meta-analysis.
reported that molnupiravir probably reduces hospitalisation (odds ratio 0·54 [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} CI 0·30 to 0·90]; based on five trials) and time to symptom resolution (–3·3 days [–4·8 days to –1·6 days]; based on three trials). WHO therefore advises that molnupiravir might benefit outpatients with mild-to-moderate COVID-19 at the highest risk of adverse outcomes.
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
of 1433 outpatients with confirmed SARS-CoV-2 infection recruited in more than 20 countries, molnupiravir was associated with a reduced risk of all-cause hospitalisation or death (risk difference −3·0{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} [95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} CI –5·9{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} to −0·1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}]). The MOVe-OUT participants were unvaccinated, all had at least one risk factor for progression to serious illness, and were most commonly infected with delta, gamma, and mu SARS-CoV-2 variants.
Merck Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study.
Participants in PANORAMIC were mostly multiply vaccinated, older, and infected with omicron.
The reported benefit of molnupiravir in MOVe-Out was lower in the final analysis than in the initial interim results, and the post-interim data in isolation did not suggest benefit.
Making statistical sense of the molnupiravir MOVe-OUT clinical trial.
Possible explanations for this seeming reduction in benefit include changes in circulating SARS-CoV-2 variants, recruitment from new sites with different hospitalisation policies, and recruitment of participants with less severe illness.
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
In PANORAMIC, molnupiravir was associated with faster alleviation of fever, cough, fatigue, and feeling generally unwell, and shortened time to self-reported recovery. We postulate that molnupiravir might also have shortened the time to resumption of normal activities, which is closely related to the duration of feeling unwell, but we did not measure this outcome directly.
Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial.
Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial.
Exploratory analyses from MOVe-OUT showed that, compared with placebo, molnupiravir was associated with a greater reduction from baseline in mean viral load at days 3, 5, and 10.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
of 180 participants (both vaccinated and unvaccinated) molnupiravir was associated with reduced time to a negative PCR test (8 days vs 11 days). These findings are consistent with findings in PANORAMIC of a reduction in viral detection and viral load with molnupiravir plus usual care compared with usual care from day 4 onwards in a subgroup of the trial cohort. The proportion of participants with undetectable viral loads in the usual care group was 3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} by day 7, whereas based on the placebo group in the FLARE trial
Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
we would have expected this proportion to be 15–36{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}. Nonetheless, we noted a significant increase in the proportion of patients with undetectable viral loads in the molnupiravir plus usual care group compared with the placebo group. Viral whole-genome sequencing, pharmacodynamic analyses, and antibody modelling are underway to further investigate this finding.
PANORAMIC is the largest randomised trial of novel antiviral agents for COVID-19 so far. Ascertainment for the primary outcome was 97{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}. Participants were randomised a mean of 2 days and treated a mean of 3 days after symptom onset, and nearly all participants reported full compliance with their assigned treatment.
The design of PANORAMIC breaks with the traditional trial paradigm in which the participant comes to the research. The study of molnupiravir in PANORAMIC allowed for remote recruitment of participants from all four UK devolved administrations, irrespective of where people live or receive their health care. PANORAMIC strives to be a democratic trial, with a proactive outreach strategy led by the trial’s national pharmacy and inclusion and diversity lead. These efforts are important: research suggests that one reason for the often-low representation of people from diverse and minority ethnic backgrounds in clinical studies is that these populations find it more difficult to access research.
Are racial and ethnic minorities less willing to participate in health research?.
Yet these groups are often at increased risk of more and worse disease, as is the case with COVID-19. The ability of participants to be recruited, enrolled, and followed up without having to leave their homes reduced the burden of trial procedures on participants and might have reduced the spread of infection. Participants from ethnic minorities accounted for nearly 6{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of the trial population (whereas ethnic minorities account for 12{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of the population of England and Wales in the age groups recruited). However, the mean age of participants in PANORAMIC was 56·6 years, and there are proportionally fewer people of minority ethnic origin in older age groups in the UK.
The proportion of PANORAMIC participants older than 50 years who were from ethnic minorities was 5·1{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}, which is broadly similar to that in the English and Welsh general population (6·3{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}).
The primary analysis estimated a 33{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} probability of superiority—that is, there is a 33{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} chance that the addition of molnupiravir to usual care reduces hospitalisation or death by any non-zero amount. The analysis can also be interpreted in terms of inferiority: the estimated probability of molnupiravir use increasing hospitalisation or death by any non-zero amount is 67{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc}. The primary analysis does not provide compelling evidence for either conclusion. The 95{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} BCI for the primary outcome (0·81–1·41) indicates that plausible effects for molnupiravir could range from a 19{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} reduction to a 41{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} increase in the risk of hospitalisation or death. Taken together, these estimates suggest that the effect of molnupiravir is modest (in either direction). Under the best-case assumption of a 19{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} risk reduction, the number needed to treat in the population is 677.
Although it is critical to ensure that patients who are likely to benefit receive treatment with antiviral agents, use of antivirals in patients unlikely to benefit risks driving resistance, wastes resources, and potentially exposes people unnecessarily to harm. There is a theoretical risk that molnupiravir use at scale could lead to the emergence of new SARS-CoV-2 variants. This risk is being assessed in PANORAMIC trial’s virology substudy. However, animal studies
β-d-N 4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome.
suggest that viral mutations induced by molnupiravir are likely to lead to reduced viral viability, with low potential to develop resistant strains. Analysis of mutation frequency and the infectivity of persisting strains after molnupiravir use is underway and will be reported separately.
The open-label design of PANORAMIC means that we cannot estimate the proportion of the effect of molnupiravir on symptoms that might result from any placebo effect. However, the primary outcome in PANORAMIC (non-elective hospitalisation or death) is unlikely to be affected by a placebo effect. Furthermore, the virology substudy findings support a mechanism to explain self-reported reduction in illness duration. We can also draw some positive inference from the four reported intervention arms of the open-label community PRINCIPLE trial of repurposed medicines for COVID-19, in which similar patient-reported measures of improvement were used and only one intervention (inhaled budesonide) was associated with a meaningful effect on self-reported symptoms.
Platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk.
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
and facilitate a more realistic cost-effectiveness and cost-utility assessment, given that subsequent health-care utilisation might be influenced by knowledge of receiving a potentially active treatment.
Patients with COVID-19 who were extremely clinically vulnerable, although eligible for participation in PANORAMIC, were referred and encouraged to access and be considered for monoclonal antibody or antiviral treatment directly from the NHS. Our findings might therefore be less applicable to patients in this highest-risk category.
In conclusion, this trial of vaccinated adults at increased risk of an adverse outcome and unwell with confirmed SARS-CoV-2 infection showed that early treatment with molnupiravir did not reduce already low hospital admission or deaths. Our findings suggest that, in a highly vaccinated population at high risk (but not the highest risk) of complications from COVID-19, the avoidance of hospitalisation and death is primarily achieved via extensive vaccination. The benefits of molnupiravir in terms of faster time to recovery, reduced contact with general practitioner services, and reduced viral load need to be considered in the context of the prevailing disease, burden on health-care services, drug-acquisition cost, social circumstances, cost-effectiveness, and opportunity costs. Further virological and health economic analyses are underway, and participants are still being followed up to establish the effect of acute COVID-19 treatment with molnupiravir on longer-term symptoms.
PANORAMIC collaborative group
Akosua A Agyeman, Tanveer Ahmed, Damien Allcock, Adrian Beltran-Martinez, Oluseye E Benedict, Nigel Bird, Laura Brennan, Julianne Brown, Gerard Burns, Mike Butler, Zelda Cheng, Ruth Danson, Nigel de Kare-Silver, Devesh Dhasmana, Jon Dickson, Serge Engamba, Stacey Fisher, Robin Fox, Eve Frost, Richard Gaunt, Sarit Ghosh, Ishtiaq Gilkar, Anna Goodman, Steve Granier, Aleksandra Howell, Iqbal Hussain, Simon Hutchinson, Marie Imlach, Greg Irving, Nicholas Jacobsen, James Kennard, Umar Khan, Kyle Knox, Christopher Krasucki, Tom Law, Rem Lee, Nicola Lester, David Lewis, James Lunn, Claire I Mackintosh, Mehul Mathukia, Patrick Moore, Seb Morton, Daniel Murphy, Rhiannon Nally, Chinonso Ndukauba, Olufunto Ogundapo, Henry Okeke, Amit Patel, Kavil Patel, Ruth Penfold, Satveer Poonian, Olajide Popoola, Alexander Pora, Vibhore Prasad, Rishabh Prasad, Omair Razzaq, Scot Richardson, Simon Royal, Afsana Safa, Satash Sehdev, Tamsin Sevenoaks, Divya Shah, Aadil Sheikh, Vanessa Short, Baljinder S Sidhu, Ivor Singh, Yusuf Soni, Chris Thalasselis, Pete Wilson, David Wingfield, Michael Wong, Maximillian N J Woodall, Nick Wooding, Sharon Woods, Joanna Yong, Francis Yongblah, Azhar Zafar.
Contributors
CCB and JSN-V-T conceived the study. CCB is chief investigator and PL and FDRH are co-chief investigators. BRS, L-MY, JH, MD, CCB, FDRH, PL, GH, OAG, JD, NMR, DBR, SP, DML, JFS, KH, PE, and OvH, contributed to trial design. EO, JA, PE, LL, EH, LC, MB, MM, MC, SB, CB, JCD, IR-W, AC-S, HA, and DB were responsible for study implementation and data acquisition. HR led the clinical team. L-MY, BRS, JH, VH, UG, JM, MAD, CTS, MF, LM, SM, and NSB contributed to statistical analysis. SK, DBR, GH, NMR and MD contributed to safety assessments, monitoring, and oversight of drug interactions. MGP was the national pharmacy and inclusion and diversity lead for the trial. SP and MEP ran the economic assessments. JFS, DML, and JB led the virology sub-study. GH led on patient and public involvement. JC led on the information systems. MB led on data management. CCB, PL, OAG, NMR, SP, DBR, KH, MGP, BRS, EO, JD, DML, SK, NF, NPBT, PE, JFS, JB, JA, MD, T-AM, MEP, GH, ML, BDJ, NDH, MM, JC, EH, LC, MB, MA, OvH, AU, L-MY, and FDRH were members of the trial management group, supporting site recruitment, activity, and delivery. All authors contributed to trial conduct. OAG and CCB produced the first draft of the Article. CCB, OAG, L-MY, PL, FDRH, GH, NMR, DBR, MGP, DML, JFS, PE, JB, JD, SP, JSN-V-T, and SK contributed substantially to subsequent drafts of the Article. All authors critically revised the manuscript. CCB, PL, and FDRH had final responsibility for the decision to submit for publication. CCB and L-MY had full access to and verified all study data.
Data sharing
Qualifying researchers who wish to access our data should submit a proposal with a valuable research question. Proposals will be assessed by a committee formed from the trial management group, including senior statistical and clinical representation. Data will be shared in accordance with the data sharing policy of Nuffield Department of Primary Care Health Sciences.
Declaration of interests
JSN-V-T was seconded to the Department of Health and Social Care, England from October, 2017, to March, 2022, and reports lecture fees from Gilead and fees for participation on an advisory board for F Hoffmann-La Roche. KH is a member of the Health Technology Assessment General Committee and Funding Strategy Group, and Research Professors Funding Committee at the UK National Institute for Health and Care Research (NIHR), received a grant from AstraZeneca (paid to their institution) to support a trial of Evusheld for the prevention of COVID-19 in high-risk individuals, and is an independent member of the independent data monitoring committee for the OCTAVE-DUO trial of vaccines in individuals at high risk of COVID-19. DML has received grants or contracts from LifeArc, the UK Medical Research Council, Bristol Myers Squibb, GlaxoSmithKline, the British Society for Antimicrobial Chemotherapy, and Blood Cancer UK, personal fees or honoraria from Biotest UK, Gilead, and Merck, consulting fees from GlaxoSmithKline (paid to their institution), and conference support from Octapharma. DBR has received consulting fees from OMASS Therapeutics and has a leadership and fiduciary role in the Heal-COVID trial TMG. BRS, JM, MAD, CTS, NSB, and MF report grant money paid to their employer from the University of Oxford for the statistical design and analyses of the PANORAMIC trial. JM has also participated on data and safety monitoring boards as part of his employment with Berry Consultants. ML is a member of the data monitoring and ethics committee of RAPIS-TEST (NIHR efficacy and mechanism evaluation). SK reports grants from GlaxoSmithKline, ViiV, Ridgeback Biotherapeutics, Vir, Merck, the UK Medical Research Council, and the Wellcome Trust (all paid to his institution), speaker’s honoraria from ViiV, and donations of drugs for clinical studies from ViiV Healthcare, Toyama, and GlaxoSmithKline. JFS has participated on a data safety monitoring board for GlaxoSmithKline. MA has received grants from the Blood and Transplant Research Unit, Janssen, Pfizer, Prenetics, Dunhill Medical Trust, the BMA Trust (Kathleen Harper Fund), and Antibiotic Research UK (all of which were paid to their institution), and consultancy fees from Prenetics and OxDx. MA reports a planned patent for Ramanomics, has participated on data safety monitoring boards or advisory boards for Prenetics, and has an unpaid leadership or fiduciary role in the E3 Initiative. NPBT has received payment for participation on an advisory board from MSD (before any knowledge or planning of this trial). OvH has received consulting fees from MindGap (fees paid to Oxford University lnnovation), has participated on data safety monitoring boards or advisory boards for the CHICO trial, and has an unpaid leadership or fiduciary role in the British Society of Antimicrobial Chemotherapy. AU has received consulting fees and payment or honoraria from MSD, GlaxoSmithKline, and Gilead. NF has received consulting fees from Abbott Diagnostics and GlaxoSmithKline, is a member of the PRINCIPLE trial data safety monitoring board and the NIHR Health Technology Assessment General Funding Committee, and has stocks in Synairgen. JB has received consulting fees from GlaxoSmithKline (paid to her institution). All other authors declare no competing interests.
Acknowledgments
This study was funded by the NIHR (NIHR135366). KH and SP are co-investigators on this grant, and DMI was a co-applicant. CCB received support as an NIHR senior investigator, from the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative, and from the NIHR Health Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance. FDRH is part-funded by the NIHR Applied Research Collaboration and the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative. GH is funded by an NIHR advanced fellowship and by the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative (MIC). JD is funded by the Wellcome Trust PhD programme for primary care clinicians (216421/Z/19/Z). SP receives support as an NIHR senior investigator (NF-SI-0616-10103) and from the UK NIHR Applied Research Collaboration Oxford and Thames Valley. OAG receives funding from the European Clinical Research Alliance on Infectious Diseases (project number 101046109). JB receives supports as an NIHR senior investigator and from the University College London Hospitals NIHR Biomedical Research Centre. JFS received a UK Medical Research Council project grant (MR/X004724/1) that contributed to the design of the virology study. HA is supported by an NIHR Advanced Fellowship funded by Health and Care Research Wales. JFS has received research grants from the UK Medical Research Council (MR/X004724/1, MR/W015560/1), the Wellcome Trust, NIHR, and the Drugs for Neglected Diseases Initiative, all of which were paid to his institution. OvH has received an NIHR Development and Skills Personal Award. T-AM reports grant funding from Cardiff University through an NIHR award to the University of Oxford. NF reports receiving NIHR grant funding. ML and PL report funding from the NIHR for PANORAMIC. We thank all participants in the study, all participating general practices, NHS COVID-19 treatment services, and other health and social care organisations supporting the trial for their work and support, our patient and public involvement contributors, the trial steering and data monitoring and safety committees, primary care colleagues in the NIHR Clinical Research Network (lead network: Thames Valley and South Midlands), Health and Care Research Wales, NHS Research Scotland, the Health and Social Care Board in Northern Ireland, the NIHR, and the Therapeutics Task Force, NHS DigiTrials, the Intensive Care National Audit and Research Centre, Public Health Scotland, the National Records Service of Scotland, the Secure Anonymised Information Linkage at the University of Swansea, and Health and Social Care Northern Ireland. The views expressed in this Article are the authors’ and not necessarily those of the NIHR or the Department of Health and Social Care.
Supplementary Material
References
1.
Toots M
Yoon JJ
Cox RM
et al.
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.
Sci Transl Med.2019; 11eaax5866
2.
Fischer 2nd, WA
Eron Jr, JJ
Holman W
et al.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Sci Transl Med.2022; 14eabl7430
3.
Molnupiravir: coding for catastrophe.
Nat Struc Mol Biol.2021; 28: 706-708
4.
Cox RM
Wolf JD
Plemper RK
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
Nat Microbiol.2021; 6: 11-18
5.
Wahl A
Gralinski LE
Johnson CE
et al.
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
Nature.2021; 591: 451-457
6.
Rosenke K
Hansen F
Schwarz B
et al.
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
Nat Commun.2021; 122295
7.
Khoo SH
Fitzgerald R
Fletcher T
et al.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother.2021; 76: 3286-3295
8.
Painter WP
Holman W
Bush JA
et al.
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2.
Phase 2/3 trial of molnupiravir for treatment of COVID-19 in nonhospitalized adults.
NEJM Evidence.2021; 1EVIDoa2100043
10.
Jayk Bernal A
Gomes da Silva MM
Musungaie DB
et al.
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
N Engl J Med.2022; 386: 509-520
11.
Singh S
Kumar Mitra A
Arora N
Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19.
12.
Khoo SH
FitzGerald R
Saunders G
et al.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis.2022; ()
13.
Master protocols to study multiple therapies, multiple diseases, or both.
N Engl J Med.2017; 377: 62-70
14.
National Institute for Health and Care Excellence
COVID-19 rapid guideline: managing COVID-19.
National Institute for Health and Care Excellence, London2021
15.
Department of Health and Social Care
Coronavirus: medical treatments.
16.
Interim clinical commissioning policy: neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19.
17.
Gastine S
Pang J
Boshier FA
et al.
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies.
Clin Pharmacol Ther.2021; 110: 321-333
18.
Laouénan C
Guedj J
Mentré F
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.
BMC Med Res Methodol.2013; 13: 1-10
19.
Agarwal A
Rochwerg B
Lamontagne F
et al.
A living WHO guideline on drugs for COVID-19.
BMJ.2020; 370m3379
20.
Siemieniuk RA
Bartoszko JJ
Ge L
et al.
Drug treatments for COVID-19: living systematic review and network meta-analysis.
BMJ.2020; 370m2980
21.
Lawrence J
Mirchandani M
Hill A
Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients.
Research Square.2022; ()
22.
Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study.
23.
Omicron variant and booster COVID-19 vaccines.
Lancet Respir Med.2022; 10: e17
24.
Thorlund K
Sheldrick K
Meyerowitz-Katz G
Singh S
Hill A
Making statistical sense of the molnupiravir MOVe-OUT clinical trial.
Am J Trop Med Hyg.2022; 106: 1301-1304
25.
Little P
Stuart B
Moore M
et al.
Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial.
Lancet Infect Dis.2013; 13: 123-129
26.
Little P
Rumsby K
Kelly J
et al.
Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial.
JAMA.2005; 293: 3029-3035
27.
Lowe DM
Brown L-AK
Chowdhury K
et al.
Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
PLoS Med.2022; 19e1004120
28.
Wendler D
Kington R
Madans J
et al.
Are racial and ethnic minorities less willing to participate in health research?.
PLoS Med.2005; 3: e19
29.
Population of England and Wales.
30.
UK Office for National Statistics
2011 Census.
31.
Abdelnabi R
Foo CS
Kaptein SJ
et al.
The combined treatment of molnupiravir and favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
EBioMedicine.2021; 72103595
32.
Urakova N
Kuznetsova V
Crossman DK
et al.
β-d-N 4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome.
J Virol.2018; 92: e01965-e01977
33.
Hayward G
Butler CC
Yu L-M
et al.
Platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk.
BMJ Open.2021; 11e046799
34.
Butler CC
Yu L-M
Dorward J
et al.
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Lancet Respir Med.2021; 9: 1010-1020
35.
Dorward J
Yu L-M
Hayward G
et al.
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.
MANILA, Philippines – When people today consider of women’s overall health, it typically in terms of reproductive challenges – pap smears, pre-natal and fertility checks, breast tests. Mental well being issues like depression, or brain conditions like Alzheimer’s, aren’t often deemed as women’s health problems.
A far more holistic tactic to women’s health and fitness takes all these concerns and much more into thing to consider – and that’s particularly what Kindred, a new female-centric clinic in Taguig is set on accomplishing.
Kindred in the beginning operated as a telehealth platform and sooner or later introduced a brick-and-mortar clinic on December 7. In contrast to typical health care institutions, Kindred’s house is accomplished up in coloured partitions and Instagrammable interiors, earning it inviting and comforting for patients.
“When they say women’s overall health, you assume being pregnant. It’s not just about being pregnant, there is a total wide vary of women’s wellness remedies,” Kindred’s co-founder and CEO Jessica de Mesa, a previous nurse.
“Even if the issue is a gynecological affliction, there are some signs or effects of reproductive health and fitness problems that have an impact on other components of our bodies,” she mentioned.
Jessica gave the illustration of Polycystic Ovarian Syndrome (PCOS), which according to her influences 1 in 10 Filipinas. She stated that women who have PCOS working experience a whole host of signs or symptoms – from pounds obtain, zits breakouts, hair reduction or hair expansion, and despair.
“So it’s critical that the doctors have a holistic approach, for the reason that you wanna experience superior, proper? So there’s no uncomplicated cure for it. We have a dermatologist, a nutritionist to assist them drop pounds a bit, or [help with] ingesting healthful in common. That’s what a woman with PCOS goes by, it’s a large amount,” she said.
Mental overall health for gals
The clinic also gives psychological health and fitness expert services, with both of those a psychiatrist and psychologist on board for consultations. According to Jess, more than 20{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} of their individuals offer with mental wellness problems.
“What’s going on suitable now, there is so many matters we’re all dealing with ideal now…pandemic, get the job done. And all the circumstances they are going as a result of. Like PCOS [patients], for instance, they are also likely by a large amount of melancholy, due to the fact like what the hell, what’s heading on, abruptly I gained so much pounds, breaking out and every thing, the self-graphic is affected,” Jess stated.
Kindred co-founder and healthcare entrepreneur Abet Valenzuela included that apart from situational components that could have an affect on a woman’s mental well being, there are also physiological elements these as hormonal fluctuations that gals are especially vulnerable to – from PCOS to post-partum despair.
“Studies are coming out and there is proof now that females 60 to 70 are much more prone to Alzheimer’s and dementia. And that has a whole lot to do with our hormones and how we’re produced,” she explained.
“Science is getting made, and now places like Kindred and in other nations around the world that is definitely just targeted on women of all ages, on a woman’s body, on our hormones, on how our hormones affect our pounds, our psychological health and fitness,” she stated.
CO-FOUNDERS. Jess de Mesa and Abet Valenzuela are the gals at the rear of female-targeted clinic Kindred.
Sexual well being for women of all ages
Another underserved component of women’s health care is sexual health – and it is anything that Kindred also wishes to spot emphasis on. The clinic involves a pharmacy that dispenses contraception, and their sister assistance Anna delivers on-line shipping and delivery and month-to-month subscriptions to start management as well.
The clinic’s on the web community also routinely shares info and retains conversations about sexual wellness and reproductive rights.
Jess shared that all through her experience as a nurse, she cared for quite a few people who were being working with the repercussions of making an attempt to terminate their own pregnancies simply because abortion is nonetheless illegal in the place.
“It comes about each day. Females die, Filipinas die each and every working day from terminating their have being pregnant, like they get this tablet from the black market place unregulated, what their peers instructed them would get the job done for them. They close up in the healthcare facility for a couple of months, they go by means of psychological wellness issues as well simply because of that, and some women of all ages do not even survive, they really don’t even get to the healthcare facility if they start off bleeding out in their toilet. Which is what comes about a whole lot. It is insane,” she said.
“They do not know a ton about contraceptive methods, how to avoid early pregnancy…. They don’t know a ton about those people things, so we’re also big on neighborhood-developing due to the fact there is so lots of subjects that we never communicate about,”
Abet additional that women bear the brunt of some sexually transmitted disorders.
“There are sexually transmitted illnesses that have an effect on girls more than adult males. There are these silent killers as they say right, the place guys are carriers but gals choose the load of the trouble,” she mentioned.
Kindred’s aim is to foster a secure room for gals to examine these issues with their health care companies.
INVITING. Kindred’s brick-and-mortar place does not glimpse like your usual healthcare middle.
Guilt-free of charge wellness
Apart from OB-GYNE services, mental overall health treatment, and sexual health instruction, Kindred provides wellness companies, and encourages ladies to love these without the need of guilt. Some of these services include IV drips (with a concentration on professional medical advantages relatively than cosmetic effects) and conditioning schooling and session.
“We’re making an attempt to empower them to actually take treatment of them selves, irrespective of whether that is through yoga, or acupuncture, or IV drips,” Jess explained, pointing out that a whole lot of women of all ages juggle numerous obligations – from making their career, to running their house.
Ultimately, Abet pointed out that all these things need to be viewed as when it comes to women’s wellbeing care.
“Human beings, we’re a sum of all of the pieces, distinct areas. Rather of concentrating on a single portion, we’re concentrating on human beings, and we are several issues,” she reported.
“I feel the question we have to talk to is, how several situations have you been bounced all over just making an attempt to figure out what you have to have? And that’s what we’re seeking to fix, mainly because that is also a barrier to why honestly normal men and women never address their wellness difficulties. For the reason that it’s inconvenient, it is intransparent, it is time-consuming, and it’s pricey,” she explained. “Our intention is to deliver the female and the care nearer jointly.”
Kindred is situated on the next flooring of Serendra Shopping mall, Bonifacio World City, Taguig. – Rappler.com
